To check the Safety of the products

Completed

• Conditions: Healthy Male and Female subjects

• Registration Number: CTRI/2022/11/047456
• Lead Sponsor: ITC Life Sciences Technology Centre

Brief Summary

Study Objective:

The objective of this study is to evaluate the dermatological safety of the investigational products on healthy human subjects.

Study Population:

24 healthy human volunteers (Male and Female 1:1) with Skin types (Oily, Dry, Normal and Combination, 1:1:1:1 ratio).

Duration of study:

Approximately 9 days for each volunteer.

Test Site:

Between the scapula and waist of the subjects, the test site should be free of pigmentation, pimple, hair, mole or any dermatological condition that can interfere with the reading.

Patch Application:

The loaded patch system is applied at the test site of study subjects starting with the lower edge of the patch system and slowly pressing upwards till the top edge in order to squeeze out the air.

Patch Methodology:

The patch will be kept for 24 hours. The patch will be removed after 24 hours. The test sites will be wiped with a clean tissue to remove any residue prior to evaluation. Dermatologist will visually assess the skin condition of each test site at the following frequencies- 20-30 minutes’ post patch removal (0 hour reading), 24 hrs and 7 days’ post patch removal as per Draize scoring system.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-11-28
• Study Completion: 2022-12-15
• Last Update Posted: 2022-12-26

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

• 1. Subjects in age group 18.
• 65 years (both the ages inclusive). 2. Healthy male & female subjects with skin types as defined in the population details under appendix 3. Subjects with Fitzpatrick skin type III to V 4. Subjects in good health condition as per the medical screening criteria with no disease state or physical condition that the Investigator believes could interfere with the interpretation of the data. 5. Subject able to read, understand and sign an appropriate informed consent form indicating her willingness to participate. 6. Subjects willing to give a voluntary written informed consent. 7. Subjects willing to maintain the patch test in position for 24 hours. 8. Subject having not participated in a similar investigation in the past two weeks. 9. Subjects willing to come for regular follow up visits. 10. Subjects ready to follow instructions during the study period.

Exclusion Criteria

• Subjects with infection, allergy on the tested area.
• Subjects with skin allergy, antecedents or atopic subjects.
• Athletes and subjects with history of excessive sweating.
• Subjects with cutaneous disease which may influence the study result.
• Subjects on oral corticosteroid.
• Subjects participating in any other cosmetic or therapeutic trial.
• Subjects who are currently pregnant or lactating or planning to become pregnant in the period of study.
• Subjects with any history of underlying uncontrolled medical illness including diabetes, liver disease or history of alcoholism, HIV or any other serious medical illness.
• Subjects working with MSCR.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To evaluate the dermatological safety of the investigational products on healthy human subjects	Approximately 9 days for each subject.

Trial Locations

Locations (1)

MS Clinical Research Pvt. Ltd.; 🇮🇳 Bangalore, KARNATAKA, India

MS Clinical Research Pvt. Ltd.

🇮🇳Bangalore, KARNATAKA, India

Dr Navya Annam

Principal investigator

08041125934

navya@mscr.in